RedHill Reports Results of Yeliva (opaganib) in P-II Study for COVID-19

January 4, 2021 Auto Bot Clinical Trials, P-II, RedHill, reports, results, Study 0

Shots:

  • The P-II US study involves assessing Opaganib + SOC vs PBO + SOC in 40 patients requiring oxygen support in a ratio (1:1) and were followed up for ~42days post-treatment initiation
  • The study demonstrated improvement in reaching room air within 14days (52.6% vs 22.2%); improvement in reduction to 50% supplemental oxygen by Day 14 (89.5% vs 66.7%); a higher proportion of patients discharged by Day 14 (73.7% vs 55.6%), reduction in the median total oxygen requirement (AUC) over 14 days (68.0% vs 46.7%)
  • The results from the global P-II/III study in 270 hospitalized patients expected in Q1’21 and an interim DSMB futility analysis is expected in the coming weeks

Click here ­to­ read full press release/ article | Ref: Redhill Bio | Image: PR Newswire UK

The post RedHill Reports Results of Yeliva (opaganib) in P-II Study for COVID-19 first appeared on PharmaShots.